Investing.com - BioLineRx reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $0.00 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.0967 on revenue of $0.00.
BioLineRx shares are down 27.3% from the beginning of the year, still down 76.61% from its 52 week high of $6.34 set on May 4, 2021. They are under-performing the Nasdaq which is down 15.84% from the start of the year.
BioLineRx shares lost 2.46% in intra-day trade following the report.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings matched by Medtronic on February 22, who reported EPS of $1.37 on revenue of $7.76B, compared to forecasts EPS of $1.37 on revenue of $7.88B.
Zoetis Inc had beat expectations on February 15 with fourth quarter EPS of $1 on revenue of $1.97B, compared to forecast for EPS of $0.9629 on revenue of $1.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar